The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is doing this study because they want to learn more about eosinophilic gastrointestinal disorders (EGIDs).

The objective of this study is to assess the efficacy, safety, and tolerability of RZB SC induction treatment in comparison with placebo in subjects with moderately to severely active CD.

Demonstrate the safety and feasibility of rifaximin in the prevention of recurrent pouchitis after an initial episode of acute pouchitis.

EGID Partners is an online cohort of patients with eosinophilic gastrointestinal diseases (EGIDs), like eosinophilic esophagitis (EoE), eosinophilic gastritic (EG), eosinophilic gastroenteritis (EGE), and/or eosinophilic colitis (EC). It is a way to conduct important clinical research through surveys, and by filling out the initial survey, as well as follow-up surveys every 6 months, you can help answer important questions about living with EGIDs. We are also looking for people without EGIDs to provide information as well, so we can make comparisons between those do and don't have EGIDs. Adults as well as parents/caregivers of children are eligible. Find out more at www.egidpartners.org

The study intends to assess the effectiveness of a board exam curricula for a group of gastroenterology fellows. The study aims to assess how prepared this curricula makes the gastroenterology fellows feel, as well as objective impact on in-training exam scores.

For adults undergoing a standard of care biopsy for screening or surveillance of Barrett's Esophagus (BE). We are comparing two biopsy methods: Seattle biopsy versus WATS biopsy for the detection of intestinal metaplasia (change in the lining of your esophagus or 'food tube' to that of your stomach).

To learn if one kind of treatment approach, either (1) endoscopic surveillance or (2) endoscopic eradication therapy, is better, the same, or worse for treating patients with Barrett's esophagus and low-grade dysplasia.

we propose the creation of a prospective multi-center registry of patients with IBD and EIM, initially focusing on peripheral arthritis, the most common and understudied EIM, to better understand clinical course and management.

To create a multi-centered prospective registry of individuals ≥60 years ("older adults") with IBD to quantify prevalence, incidence and progression of frailty, multi-morbidity, physical and cognitive impairment

The primary objective for this registry is to prospectively study the natural history of IBD, the prevalence and incidence of comorbidities, and targeted adverse events, as well as the utilization patterns and the comparative effectiveness and comparative safety of approved IBD treatments.